Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: SOD1

Summary for SOD1

Gene information	Gene symbol	SOD1
	Ensembl ID	ENSG00000142168
	Entrez ID	6647
	Gene name	superoxide dismutase 1
	Synonyms	ALS\|ALS1\|IPOA
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: SOD1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.751099	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.282908	2.14e-40
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.385238	2.53e-22
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.362831	1.35e-35
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.303892	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.40268	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.252278	1.28e-39
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.585339	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.291301	4.29e-34
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.538777	4.78e-22
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.503124	1.04e-40
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.465486	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.409628	2.58e-17
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.328421	4.48e-06
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.370972	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	-0.409016	1.36e-15
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.912293	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.343696	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	1.02122	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.718537	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.425408	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.311424	4.13e-03
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.433721	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.709039	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.522385	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.929787	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.256679	3.42e-26

Top

Expression of SOD1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to SOD1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating SOD1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
SOD1	hsa-miR-4679	92.0949	NM_000454
SOD1	hsa-miR-513a-5p	87.6134	NM_000454
SOD1	hsa-miR-8079	84.527	NM_000454
SOD1	hsa-miR-1245a	84.527	NM_000454
SOD1	hsa-miR-4320	83.5088	NM_000454

Page: 1

Top

Motifs and transcription factors (TFs) regulating SOD1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
SOD1	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
SOD1	transfac_pro__M05479	ZNF580 (directAnnotation).
SOD1	hocomoco__KLF13_HUMAN.H11MO.0.D	KLF13 (directAnnotation).
SOD1	jaspar__MA0079.5	SP1 (directAnnotation).
SOD1	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
SOD1	transfac_pro__M04950	EGR1 (directAnnotation).
SOD1	transfac_pro__M00652	NRF1 (directAnnotation).
SOD1	taipale_tf_pairs__E2F1_HES7_RRCRCGYGYNNNNSGCGCSN_CAP_repr	E2F1; HES7 (directAnnotation).
SOD1	transfac_pro__M04866	HDAC2 (directAnnotation).
SOD1	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
SOD1	hdpi__TP73	TP73 (directAnnotation).
SOD1	metacluster_22.12	NFE2; NFE2L1 (directAnnotation).
SOD1	metacluster_22.29	NFE2 (directAnnotation).
SOD1	metacluster_22.13	MAFK (inferredBy_Orthology).
SOD1	metacluster_22.32	NFE2L2 (directAnnotation).
SOD1	swissregulon__hs__CEBPB	CEBPB (directAnnotation).
SOD1	metacluster_30.4	BACH1; BACH1; MAFG; MAFG; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2 (directAnnotation).
SOD1	metacluster_22.25	NFE2L2 (directAnnotation).
SOD1	taipale_tf_pairs__POU2F1_ELK1_NCCGGATATGCAN_CAP	ELK1; POU2F1 (directAnnotation).
SOD1	metacluster_112.5	HOXA4; PAX3; PAX7; PAX7 (directAnnotation).
SOD1	taipale_tf_pairs__ELK1_HOXA3_RSCGGTAATKR_CAP_repr	ELK1; HOXA3 (directAnnotation).
SOD1	metacluster_141.2	E2F2; E2F3 (directAnnotation).
SOD1	metacluster_141.4	GLIS2 (directAnnotation).
SOD1	jaspar__MA1483.2	ELF2 (directAnnotation).
SOD1	tfdimers__MD00208	IRF1; LTF (directAnnotation).
SOD1	jaspar__MA0776.1	MYBL1 (directAnnotation).
SOD1	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
SOD1	metacluster_2.7	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).
SOD1	taipale_cyt_meth__ZBTB2_NTTTCCGGTAMN_eDBD_meth_repr	ZBTB2 (directAnnotation).
SOD1	taipale_tf_pairs__ETV5_EVX1_RSCGGWAATKR_CAP	ETV5; EVX1 (directAnnotation).
SOD1	taipale_tf_pairs__ETV2_DRGX_RSCGGAWRYATTA_CAP_repr	DRGX; ETV2 (directAnnotation).
SOD1	jaspar__MA0748.2	YY2 (directAnnotation).
SOD1	metacluster_198.7	AHR; ZBTB14; ZBTB14; ZBTB14 (directAnnotation).
SOD1	metacluster_174.6	NFYA; NFYB; NFYB; NFYC (directAnnotation).
SOD1	transfac_pro__M05708	ZNF136 (directAnnotation).
SOD1	transfac_pro__M06688	ZKSCAN7 (directAnnotation).
SOD1	transfac_pro__M05550	SNAPC4 (inferredBy_Orthology).
SOD1	taipale_cyt_meth__ZBTB2_NTTTMCGGTWAN_eDBD	ZBTB2 (directAnnotation).
SOD1	taipale_tf_pairs__MYBL1_ONECUT2_NAACGGNNATYGANN_CAP_repr	MYBL1; ONECUT2 (directAnnotation).
SOD1	taipale_tf_pairs__ETV2_RFX5_NCCGGAAGYNNCNTAGCAACS_CAP_repr	ETV2; RFX5 (directAnnotation).
SOD1	cisbp__M02928	YY2 (directAnnotation).
SOD1	taipale_tf_pairs__HOXB2_ESRRB_TAATKRNNNNNNAAGGTCA_CAP_repr	ESRRB; HOXB2 (directAnnotation).
SOD1	taipale_tf_pairs__HOXB2_ELK1_TAATKRCCGGAAGNN_CAP_repr	ELK1; HOXB2 (directAnnotation).
SOD1	taipale_tf_pairs__POU2F1_ETV1_NCCGGATATGCAN_CAP_repr	ETV1; POU2F1 (directAnnotation).
SOD1	transfac_pro__M05597	ZNF174 (directAnnotation).
SOD1	transfac_pro__M05560	AEBP2 (directAnnotation).
SOD1	transfac_pro__M05519	FEZF2 (inferredBy_Orthology).
SOD1	yetfasco__TBP-TFIIB_1329	GTF2B; TBPL2 (inferredBy_Orthology).
SOD1	transfac_pro__M06104	ZNF16 (directAnnotation).
SOD1	transfac_pro__M06911	ZNF233 (inferredBy_Orthology).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
SOD1	"5-fluorouridine"	DB01629	small molecule
SOD1	"Arimoclomol"	DB05025	small molecule
SOD1	"Cannabidiol"	DB09061	small molecule
SOD1	"Dopamine"	DB00988	small molecule
SOD1	"Isoprenaline"	DB01064	small molecule
SOD1	"Medical Cannabis"	DB14009	biotech
SOD1	"Nabiximols"	DB14011	small molecule
SOD1	"S-oxy-L-cysteine"	DB03382	small molecule
SOD1	"Zinc acetate"	DB14487	small molecule
SOD1	"Zinc chloride"	DB14533	small molecule
SOD1	"Zinc sulfate, unspecified form"	DB14548	small molecule
SOD1	"Zinc"	DB01593	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."